BMS 180448

Drug Profile

BMS 180448

Latest Information Update: 08 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-ischaemics; Benzopyrans; Cardiotonics; Guanidines; Ischaemic heart disorder therapies; Vasodilators
  • Mechanism of Action KATP channel stimulants; Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myocardial ischaemia

Most Recent Events

  • 08 Sep 2003 Discontinued - Phase-II for Myocardial ischaemia in USA (unspecified route)
  • 14 Nov 1997 A preclinical study has been added to the pharmacodynamics section
  • 18 Sep 1997 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top